Apollo Newsletter_A4_09032016
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Cover Story<br />
<strong>Apollo</strong> Research Bulletin<br />
Liquid Biopsy for Brain Tumors<br />
AHERF researchers along with clinicians from <strong>Apollo</strong> Hospitals have established and<br />
developed a liquid biopsy diagnostic for brain tumours. AHERF has collaborated with<br />
Datar Genetics Ltd; a leading genetics service provider, to validate a non invasive<br />
blood based diagnostic of Glioblastomas (the most fatal and aggressive type of brain<br />
tumour). Both organizations have co-validated the assay and the path breaking test is<br />
likely to be introduced first at <strong>Apollo</strong> in February 2016. The liquid biopsy is one of the<br />
top 15 breakthrough technologies of 2015(MIT Tech Review). It places <strong>Apollo</strong> at the<br />
global forefront in research.<br />
Upcoming Projects in Genetics<br />
Urine based test for cervical cancer<br />
A leading U.S. based genetics company has developed<br />
a urine based HPV HR test for the screening of cervical<br />
cancer using DNA sequencing. ARI is working closely<br />
with Sapien in finalizing the collaboration. We believe<br />
that leveraging this technology cervical cancer<br />
screening will increase manifold. This shall enable us<br />
to diagnose & treat cervical cancer in time and there<br />
by impacting incidence nationally.<br />
Reccurence Monitoring for Breast cancer<br />
OncoStem Diagnostics is a US-India clinical diagnostic start-up. Sapien is collaborating<br />
with Oncostem to validate & launch a novel recurrence prediction test for breast cancer.<br />
The project is expected to be launched in India by May 2016.<br />
7
Change language